Shots:
- Sandoz has launched Pyzchiva, a biosimilar version of Stelara in the US to treat mod. to sev. plaque PsO & active PsA in adults as well as pediatric pts, plus mod. to sev. active crohn’s disease & UC in adults; expected to offer interchangeability by H1’25
- Launch follows Samsung’s settlement & license deal with J&J for the US market & commercialization agreement with Sandoz in Sep 2023. As per the Sep 2023 deal, Sandoz can market Pyzchiva in the US, Canada, EEA, Switzerland, UK & Brazil, while Samsung handles development, IP, manufacturing & supply
- Pyzchiva is a fully human anti-IL-12/IL-23 mAb that is available in pre-filled syringes (45mg/0.5mL & 90mg/mL) & single-dose vials (IV: 130mg/26 mL & SC: 45mg/0.5 mL)
Ref: Sandoz | Image: Sandoz
Related News:- Sandoz Report the EC’s Approval of Afqlir (Biosimilar, Eylea) to Treat Neovascular Age-related Macular Degeneration (nAMD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
